CUE BIOPHARMA ($CUE) posted quarterly earnings results on Tuesday, August 12th. The company reported earnings of -$0.09 per share, beating estimates of -$0.14 by $0.05. The company also reported revenue of $2,954,000, beating estimates of $2,419,455 by $534,545.
You can see Quiver Quantitative's $CUE stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CUE BIOPHARMA Hedge Fund Activity
We have seen 15 institutional investors add shares of CUE BIOPHARMA stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GC WEALTH MANAGEMENT RIA, LLC added 3,331,644 shares (+inf%) to their portfolio in Q2 2025, for an estimated $2,273,180
- VANGUARD GROUP INC added 871,484 shares (+37.6%) to their portfolio in Q2 2025, for an estimated $594,613
- GOOD LIFE ADVISORS, LLC removed 400,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $364,400
- SIGMA PLANNING CORP removed 270,760 shares (-83.0%) from their portfolio in Q2 2025, for an estimated $184,739
- BLACKROCK, INC. removed 186,041 shares (-29.3%) from their portfolio in Q2 2025, for an estimated $126,935
- HIGHTOWER ADVISORS, LLC removed 128,284 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $87,528
- ANGELES WEALTH MANAGEMENT, LLC added 120,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $81,876
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CUE BIOPHARMA Analyst Ratings
Wall Street analysts have issued reports on $CUE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citizens Capital Markets issued a "Market Outperform" rating on 04/02/2025
To track analyst ratings and price targets for CUE BIOPHARMA, check out Quiver Quantitative's $CUE forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
